BioSpecifics Technologies Corp

BioSpecifics Technologies — Investor Presentation (January 2015)

27 slides from BioSpecifics Technologies's investor presentation, Jan 12, 2015

  1. Slide 1: Innovators in the development & commercialization of injectable collagenase

    ° \4 Innovators in the development & commercialization of ‘INJECTABLE COLLAGENASE i, . BioSpecifics January 2015

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are “forward-looking statements”

  3. Slide 3: BioSpecifics is a profitable, commercial-stage biopharma company

    BioSpecifics is a profitable, commercial-stage biopharma company with attractive revenue growth opportunities emerging from the economic rights and royalties relating to the commercialization and development of collagenase clostridium histolyticum or CCH (XIAFLEX®). Lean capital structure allows for

  4. Slide 4: Vast Therapeutic Potential of CCH

    Vast Therapeutic Potential of CCH First-in-class, minimally invasive nonsurgical treatment option for conditions caused by collagen accumulation with limited current treatment options BioSpecifics has positive results in 12 indications: Dupuytren’s contracture’ Frozen shoulder’ Scarred tendons Peyro

  5. Slide 5: Marketed Indications for XIAFLEX

    Marketed Indications for XIAFLEX Revenue-Generating Products Dupuytren’s Approved in the U.S., EU, Canada & Australia; under Contracture review in Japan Peyronie’s Disease Approved in the U.S.; positive CHMP opinion in the EU

  6. Slide 6: Commercial Success of XIAFLEX in U.S.

    Commercial Success of XIAFLEX in U.S. Impressive Revenue Growth In Both Indications Total U.S. XIAFLEX revenues up 118% in 3Q14 over 3Q13 XIAFLEX U.S. net revenues for both indications were $34.6M versus $15.9M in 3Q13, a 118% increase U.S. XIAFLEX revenues up 31% in 3Q14 over 2Q14 Est. 5,863 vials

  7. Slide 7: XIAFLEX for Dupuytren's Contracture

    XIAFLEX for Dupuytren’s Contracture Collagen cord in the hand causing one or more fingers to Definition and contract toward the palm Key Complications Limits range of motion of the fingers often resulting in physical disability and impaired quality of life First and Only Also approved in Canada and

  8. Slide 8: XIAFLEX Label Expansion

    XIAFLEX Label Expansion sBLA Approved in October 2014 Treatment of up to two Dupuytren’s contracture joints in the same hand during a single office visit SDI Health LLC estimates 35 to 40% of annual Dupuytren’s contracture surgeries in U.S. are performed to treat two or more cords concurrently Based

  9. Slide 9: XIAFLEX for Peyronie's Disease

    XIAFLEX for Peyronie’s Disease Definition & Key Complications First and Only FDA- Approved PD Treatment Pre-treatment: Inelastic collagen causing penile curvature; penis can bend at 90° angle during erection in severe cases Associated with pain with erection, penile shortening, erectile dysfunction

  10. Slide 10: Peyronie's Disease Commercial Progress in U.S.

    Peyronie’s Disease Commercial Progress in U.S. Est. 9,000 total product vials shipped to physicians since launch Label allows for up to 8 injections (4 cycles of 2 injections) Estimated Vials Shipped to Physicians 000 000 4000 3000 2752 2000 1000 . aa 1Q14 2Q14 3Q14 All numbers are estimates from Au

  11. Slide 11: Commercial Progress in U.S.

    Commercial Progress in U.S. 95K patients diagnosed with 2013; likely underdiagnosed 5-6.5K patients receive invasive PD treatment annually » “Auxilium Advantage” Program helps patients and providers access XIAFLEX All Medicare beneficiaries confirmed coverage; 29 commercial plans approved treatment;

  12. Slide 12: XIAFLEX Pipeline Programs

    XIAFLEX Pipeline Programs Future Revenue-Generating Opportunities Frozen Lids Cellulite Initiation of Phase 2b in 2Q15 * Human Complete enrollment in Phase 2 in 1H15 Lipoma *Uterine Qraoing Fibroids Sail Canine Auxilium/Endo to determine development plan Lipoma *BioSpecifics-managed development prog

  13. Slide 13: CCH for Human Lipomas

    CCH for Human Lipomas Phase 2 Opt-In Study Managed by BioSpecifics Encapsulated deposits of benign fatty tumors; detected as bulges Benn ition under the skin Potential to be No FDA-approved pharmaceutical therapies available Only Approved ; ; . a Nonsurgical Therapy Surgery not practical for patient

  14. Slide 14: Positive Phase Clinical Trial Results

    Positive Phase 2 Clinical Trial Results Reported in January 2014 Open label, dose escalation Phase 2 trial: Statistically significant (p<0.0001) reduction in primary endpoint of visible surface area of lipoma as measured by caliper, combining all patients Patients in highest dose group (75% of comme

  15. Slide 15: CCH for Lipomas in Canines

    CCH for Lipomas in Canines Auxilium/Endo to Manage Development Program Lipomas can cause seriously restrict motion in older dogs Key Complications Surgery can be risky due to the use of general anesthesia - especially for older dogs ntial to be 1.7M dogs affected; 25 surgeries per vet performed (est

  16. Slide 16: CCH for Uterine Fibroids

    CCH for Uterine Fibroids New Study Results Reported in October 2014 Definition & Pain, decreased fertility, . miscarriage, heavy menstrual Key Complications bleeding and frequent urination y Potential to be Primary indication for 025 = Nonsurgical Therapy hysterectomy in U.S. (33% to SUERTE Option m

  17. Slide 17: CCH for Frozen Shoulder Syndrome

    CCH for Frozen Shoulder Syndrome Potential to be Only Approved Nonsurgical Therapy Definition & Complications Inflammation and thickening of shoulder capsule due to collagen Limits range of motion of shoulder Potential to be Common selene treatment options are often painful and can only Apri d requi

  18. Slide 18: Phase 2b Study of CCH in Frozen Shoulder

    Phase 2b Study of CCH in Frozen Shoulder Top-line Data Expected in 1Q15 Double-blind, placebo-controlled study evaluating safety and Phase 2b Study efficacy in Stage 2 (frozen stage) unilateral idiopathic frozen shoulder Patients to be randomized 3:1 to receive CCH or placebo ~300 Patients Up to 3 u

  19. Slide 19: Statistically Significant CCH Dose Response in Phase 2a Study

    Statistically Significant CCH Dose Response in Phase 2a Study 60 + 1 Statistically significant improvements in P<0.05 Comparis © Forward Flexion both the 0.58 mg(1mL) and 0.58 50 i to Exorcise Cohort} chiar Abduction mg(2mL) cohorts over baseline scores ©) External Rotation vs. the exercise-only gro

  20. Slide 20: CCH for Cellulite

    CCH for Cellulite Positive Phase 2a Top-line Results Reported in 3Q14 Skin dimpling as a result of collagen fibrous septae, occurring mainly Definition on the buttocks, lower limbs, and abdomen Significant Market Affects 85-98% of women (est.) and rarely in men Opportunity as First Nonsurgical Thera

  21. Slide 21: CCH for Cellulite

    CCH for Cellulite Initiation of Phase 2b Study Expected in 2Q15 Top-line Data from Phase 2a Study Mid and high level CCH doses demonstrated statistically significant improvement in cellulite across all endpoints 68% of mid and high dose groups reported being “Satisfied” or “Very Satisfied” with trea

  22. Slide 22: Endo to Acquire Auxilium for ~$2.6B

    Endo to Acquire Auxilium for ~$2.6B* No Impact on Royalty or Milestone Payment Structure Cash and stock transaction for approximately $2.6B » Deal expected to close in January 2015, subject to Auxilium shareholder approval - Obligations to BioSpecifics remain the same in terms of licensing, sublicen

  23. Slide 23: Auxilium/Endo Partnership for Development and Commercialization of CCH

    Auxilium/Endo Partnership for Development and Commercialization of CCH >$48M Received $48M received in licensing, sublicensing, milestone, COGS, and from Auxilium royalty payments as of September 30, 2014 Low double digit royalties as % of net sales by Auxilium/Endo putube Eayments Additional mark-u

  24. Slide 24: Corporate Highlights

    Corporate Highlights Projected Revenue Growth from Higher Royalties Vast opportunity for growth in revenues from XIAFLEX sales and approval of CCH in new indications » Strong IP portfolio Long-term patent protection for injectable collagenase: » Dupuytren’s Contracture: XIAFLEX has Orphan Drug prote

  25. Slide 25: Consistently Profitable Annually

    Consistently Profitable Annually 3Q14 Financial Highlights For the quarter For the year ended ended 09/30/14 12/31/13 (unaudited) (unaudited) Cash and equivalents, short term investments $ 17,500,003 $ 12,591,825 Income Statement Revenues $ 4,012,787 $ 14,467,240 Other income 8,121 26,202 Costs and

  26. Slide 26: Anticipated Upcoming Milestones

    Anticipated Upcoming Milestones Upcoming Milestones *Human Lipomas QO Complete enrollment in Phase 2 placebo-controlled opt-in trial in 1H15 Mi er Q Ongoing pre-clinical studies; refine development plan puytren’s Caen Q Decision on approval by PMDA in Japan expected by mid-2015 ie’s pone: O Final EM

  27. Slide 27: Innovators in the development & commercialization of injectable collagenase

    Innovators in the development & commercializationof | Qs ECTABLE = t- COLLAGEN Gail B ioSpecifics January 2015 TECHNOLOGIES CORP.

Biospecifics Technologies — Investor Presentation (January 2015) on 6ix